Catalyst Pharmaceuticals
Manufacturing · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
355 Alhambra Cir Ste 801, Coral Gables, ...Phone Number
(305) 420-3200Website
www.catalystpharma.comRevenue
$597 MillionStock Symbol
CPRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Explore more
Catalyst Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Catalyst Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Catalyst Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Catalyst Pharmaceuticals launches new products
Check if Catalyst Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Catalyst Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Catalyst Pharmaceuticals
Funding: Get notified immidiatlly once Catalyst Pharmaceuticals has new funding data
Click to see if Catalyst Pharmaceuticals had a recent Job posting/layoffs
Catalyst Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Catalyst Pharmaceuticals
Compare insights from companies similar to Catalyst Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$191.6M
201-500
Private
$300M
2017
PP
Pamela Papino-WoodGlobal Vice President, Medical Operations & Excellence
Company Profile Activity
Activity Insights
Catalyst Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Catalyst Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals financials insights
Gather financial insights about Catalyst Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Stock Offering
$20.1M
Catalyst Pharmaceuticals Tech Stack
A closer look at the technologies used by Catalyst Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Contracts
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Hiring Plans
Catalyst Pharmaceuticals has more open roles in Human Resources than it has had at any time in the past 12 months. Technologies mentioned include: Microsoft SharePoint.
Hiring Plans
Open Position
Catalyst Pharmaceuticals News & Media
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) stockholders approved the company’s proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting. Patrick J. McEnany, chairman of Catalyst’s board of directors, presidSolaris Energy Infrastructure Set to Join S&P SmallCap 600
NEW YORK, July 9, 2026 /PRNewswire/ -- Solaris Energy Infrastructure Inc. (NYSE: SEI) will replace Catalyst Pharmaceuticals Inc. (NASD: CPRX) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 15. Angelini Pharma S.p.A. is acquiring Catalyst...Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical DosesAre CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Catalyst Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic... Read More
